Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2 Study of EG-70 as an Intravesical Administration to Patients With BCG Unresponsive Non-Muscle Invasive Bladder Cancer (NMIBC) and High-Risk NMIBC Patients Who Are BCG Naïve or Received Incomplete BCG Treatment

NCT04752722 is registered in ClinicalTrials.gov with enGene, Inc. as lead sponsor.

NCT NCT04752722
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04752722 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2 Study of EG-70 as an Intravesical Administration to Patients With BCG Unresponsive Non-Muscle Invasive Bladder Cancer (NMIBC) and High-Risk NMIBC Patients Who Are BCG Naïve or Received Incomplete BCG Treatment
Lead sponsor
enGene, Inc.
Phase
Phase 1/2
Overall status
Recruiting
Start date
April 22, 2021
Completion date
October 30, 2030
Enrollment
350 (estimated)
Sites
102

Conditions

As the registry lists them; a condition with its own page is linked.

non-muscle invasive bladder cancer, non-muscle invasive bladder cancer with carcinoma in situ, superficial bladder cancer